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Abstract
Background: There is now strong evidence that preventive oral antiretroviral therapy can moderately reduce likelihood of
HIV infection. This concept is called HIV pre-exposure prophylaxis (PrEP). Premature closures of some previous PrEP clinical
trials, secondary to ethical concerns, did not stop research. We aimed to appraise the extent of ethics considerations
reporting in PrEP study documents.
Methods: We conducted a systematic quantitative ethics appraisal, grounded in PrEP literature and using eight principles
proposed by Ezechiel Emanuel. We developed an a priori checklist of 101 evidence-based ethics items. We obtained
protocols for eleven of nineteen clinical controlled studies identified. Two reviewers independently appraised study
documents against the checklist. Ethics appraisal was synthesized using adjusted percentages of items reported.
Results: On average, 58% of the 101 ethics items were mentioned or addressed in documents, with variations noted both
across studies and across principles. Considerations pertaining to social value were least reported (43% of checklist items, on
average) whereas considerations related to informed consent and favorable risk-benefit ratio were most reported (75% of
checklist items, on average).
Discussion: Some PrEP studies reportedly address more ethics considerations than others but, overall, ethics considerations
reporting could be much improved. While this review does not allow us to comment on the actual execution of HIV PrEP
trials, it is a reminder that optimism generated by potentially effective interventions should not overshadow the importance
of ethics in research design and development. Improving ethics reporting might improve the perceived value of PrEP
research and subsequent data.
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Introduction
Pre-exposure prophylaxis (PrEP) is an approach whereby
preventive treatment is taken by someone without a certain
condition, before exposure to agent(s) causing that condition. HIV
PrEP semantically encompasses all preventive approaches aiming
at reducing the susceptibility of seronegatives to HIV infection, in
anticipation of a high risk exposure. So, stricto sensu, all of the
following belong to HIV PrEP: behaviors and interventions for the
control of sexually transmitted diseases, male/female condom use,
male circumcision, experimental prophylactic vaccines, vaginal
and rectal experimental microbicides (containing HIV antiretro-
virals or not), and experimental systemic administration of HIV
antiretrovirals (oral or parenteral).
The trend has been to associate PrEP to microbicides but also,
and more often, to oral antiretrovirals (ARVs) for primary HIV
prevention. For our study, we opted to follow the definition of
some influential stakeholders who reserve the acronym PrEP to the
latter (e.g., www.cdc. /hiv/prep, www.avac.org). Among key
differences between microbicides and oral ARVs, antiretrovirals
tested for prevention are already available on the market. This
means, among other ethical challenges, that oral ARVs for PrEP
can be provided ‘‘off-label’’ to seronegatives by professionals or
patients with access to these drugs. Indeed, some people may
choose, for whatever reason, not to wait for official endorsement of
PrEP regimen by competent public health authorities.
The oral PrEP concept has been applied to HIV through
experimental clinical use of therapeutic antiretrovirals for about a
decade [1]. Because oral antiretrovirals currently tested in humans
are already marketed, PrEP could become the next available new
technology for HIV biomedical prevention. The proof-of-concept
has recently been demonstrated for oral daily emtricitabine/
tenofovir in men having sex with men, with a 44% reduction in
seroconversion risk [2]. Although these results are encouraging,
this level of efficacy was deemed insufficient to justify large scale
implementation.
Going back just a few years, HIV PrEP research faced serious
challenges. In 2004–2005, three PrEP trials were prematurely
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govclosed (Cambodia [3], Malawi [4], West Africa [5]). In all cases,
decision to close study sites was not based on data analyses but
followed ethical concerns publicly voiced by community advocates
[6–8]. Also, investigators of two effectiveness studies (in Botswana)
experienced methodological dilemmas in trial execution. These
issues resulted in premature termination to allow for a switch of
test-drug (in 2007), for one trial [9], and to the inability to assess
effectiveness, for the other (in 2009) [10].
Following the ‘‘community-triggered’’ early closures, interna-
tional stakeholders were consulted to determine what had gone
wrong [11]. Methodological and ethics guidelines specific to
biomedical HIV prevention research ensued [12–14]. Although
those guidelines were developed to positively influence future PrEP
research conduct, it is unclear whether they have been taken up by
PrEP investigators, regulators and sponsors. Meanwhile, the
number of HIV PrEP clinical trials has been growing [15], as
has HIV PrEP funding, with a cumulative 173 million dollars
invested, between 2002 and 2009 [16].
Our study aimed to 1) appraise the extent to which ethics
considerations are reported in HIV oral PrEP study documents and
2) identify the least and the most reported ethics considerations.
Methods
Identification of eligible studies and acquisition of source
documents
A systematic search of multiple information sources identified
prospective clinical trials designed to test approved systemic
antiretrovirals for HIV PrEP, in humans [15]. We obtained trials’
descriptions from trial registries (www.clinicaltrials.gov). Unless full
protocols and consent forms were found online (www.mtnstopshiv.
org), we communicated directly with investigators or sponsors to
request last approved versions. Published trial reports were also
retrieved (Medline, Embase).
Ethics analysis framework
We, the three authors of this paper, developed a checklist a
priori, in a stepwise process. MBK was then a graduate student who
had previously written an essay on the ethics of the PrEP trial
stopped in Cameroon (http://mk-publications-en.yolasite.com/
resources/Kokolo2005_unpublished.pdf). DAF is a methodologist
and senior scientist with expertise in clinical trials design and
bioethics (www.ohri.ca/profiles/fergusson.asp). DWC is a medical
doctor, an infectious diseases specialist and a senior scientist with
expertise in trials involving resource-limited countries (www.ohri.
ca/profiles/cameron.asp).
First, we identified guidance documents of reference. We
considered the 19 guidance points proposed as Ethical Considerations
in Biomedical HIV Prevention Trials by UNAIDS and WHO [13]. We
also retained the Institute Of Medicine’s 43 recommendations on
Methodological Challenges in Biomedical HIV Prevention Trials [12]. For
simplicity and for synthesis purposes, we used Emanuel et al.’s
Ethical Principles and Benchmarks for Multinational Clinical Research [17]
as our overall framework. This model features 31 benchmarks
classified in eight principles: collaborative partnership, social value,
scientific validity, fair selection of study population, favorable risk-benefit ratio,
independent review, informed consent, and respect for recruited participants and
study community. Additionally, we identified reported ethical issues
about HIV PrEP, through a screening of peer-reviewed articles
published until 2008.
Second, we made an initial list of items that would make up our
checklist. Our intent was to have an inventory of conditions that
should be fulfilled or at least discussed, in accordance with the
ethics guidance documents we retained. While going through each
guidance document, we extracted concepts of ethical consider-
ations deemed relevant to HIV oral PrEP. Key papers from our
literature review provided a few more items. We reviewed the
checklist and discussed its comprehensiveness.
Third, we standardized the formulation of our items. Each item
was an affirmative stand-alone statement representing a practical
ethical consideration. Because our ethics guidance sources
presented many redundant considerations within and across
documents, we removed repetitive statements. After three rounds
of discussion, we reached a consensus to retain 101 checklist items.
Fourth, we structured our checklist by domains. Each checklist
item was categorized as belonging to one of the 31 benchmarks,
hence building a second level of specification for the 8 principles,
as suggested by Emanuel et al. [17]. We numbered checklist items,
for easier referencing. Clarifications and references to original
ethics guidelines were inserted as endnotes to facilitate interpre-
tation and harmonize appraisal by independent reviewers. For
instance, under Community Participation principle, item number 12 -
‘‘standard ethics training given to research staff in all study sites’’ - was
drawn from a sentence in UNAIDS/WHO’s guidance document:
‘‘Research literacy programs that include ethics training for study staff can
facilitate and enhance cooperation with civil society groups.’’ (Guidance
point 2: Community Participation). And under Scientific Validity
principle, item number 31 - ‘‘description of strategies for achieving accrual
rate goals and for maximizing retention’’ - was derived from an IOM’s
recommendation stating that ‘‘…investigators should place a high
priority on developing effective strategies to achieve accrual rate goals and to
minimize losses to follow-up.’’ (Chapter 6-Design Considerations:
Recruitment and Retention).
101 data items for eight ethics principles
Collaborative partnership (6 benchmarks) has 20 items; social value (4
benchmarks) has 7; scientific validity (3 benchmarks) has 33; fair
selection of study population (3 benchmarks) has 6; favourable risk-benefit
ratio (2 benchmarks) has 4; independent review (3 benchmarks) has 10;
informed consent (5 benchmarks) has 12; and respect for recruited
participants and study community (5 benchmarks) has 9.
Data extraction
The ethics checklist was piloted on two included studies and
amended to optimize extraction process. Each study document
obtained was fully reviewed by two independent assessors, who
were specifically trained for data extraction. Our intent was to
assess the reporting of ethics considerations in PrEP study
documents. So, investigators were not surveyed; neither were they
queried on data items found or not found in documents. In case of
inconsistency across source documents pertaining to the same
study, study report prevailed on consent form, which prevailed on
protocol, which prevailed on registry file.
For each study, a given item was checked if 1) corresponding
information was clearly identified in a source document and 2)
nothing in the rest of same document contradicted that
information. Discordant assessments were resolved consensually
or with assistance of a third assessor.
Statistics
Disaggregated counts of items checked were electronically
captured and analyzed in ExcelH (Microsoft, Inc., version 2003)
and in SASH (version 9.1: SAS Institute Inc., Cary, NC, United
State of America). We counted the number of studies (n) for which
we found each checklist item. In addition, we calculated the
percentage of items checked, for each individual study, at principle
level. The denominator used was smaller than the total number of
items whenever there were considerations not applicable to a study
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calculated the percentage of items checked, for each study, across
principles. Because the number of items varied under each
principle, we adjusted these proportions through a direct
standardization [18], assuming all principles had the same weight
[19].
Median percentages of ethics items reported were calculated,
across studies and across principles (rounded up when first decimal
equalled 5). Ethical principles for which the ethics considerations
were least reported or most reported were identified using those
medians. Sub-group analyses were also based on a comparison of
median percentages computed. We chose a posteriori to assess
influence of studies’ primary question (efficacy/effectiveness versus
other primary outcomes), sites location (enrolment involving
populations in high income countries versus enrolment not
involving them), and progress status (studies with early closure of
one or all study sites versus studies ongoing or completed as
planned). Our literature review had suggested that such factors
could impact trials’ acceptability, which has strong links with
ethics. For progress status, we further compared median
percentages of ethics items reported between studies closed early
on the initiative of investigators (e.g., a priori defined futility) and
studies closed early following community pressure. Analysis was
restricted to eligible studies for which at least an approved protocol
could be obtained.
Results
Out of 19 HIV oral PrEP trials identified, we excluded one that
focused on topical PrEP (compared to oral tenofovir taken only
once) [20,21] and three that were still in protocol development
phase at the time we completed our data collection [22–24]. We
also excluded four studies for which only one target document
(registry file or report) was obtained [1,4,25,26]. In those cases,
contacted investigators did not respond (n=1), declined to release
documents (n=2) or explained that protocol had never been
approved (n=1). All four target study documents (registry file [27–
29], protocol [30–32], consent form [33–35], report [2,3,5]) were
obtained for three studies, and three (registry file [36–43], protocol
[44–51], consent form [45–49,51–53]) were obtained for eight
studies. Those 11 studies were included in our ethics analysis
(Tables 1 and 2).
PrEP trials analyzed
The 11 trials analyzed were first registered between 19 February
2004 and 24 June 2008, and were scheduled to start between June
2004 and June 2009. At the time we completed our analysis, 3
trials were completed, 5 had closed prematurely, and 3 were
ongoing. Nine trials analyzed had efficacy/effectiveness as a
primary outcome, while the other two had only safety/tolerability,
adherence, acceptability, and/or pharmacokinetics as primary
outcomes. Eight trials were to recruit in low or middle income
countries only, while 3 were to include sites in the United States of
America (USA). Trials were designed to test daily tenofovir and/or
oral emtricitabine oral pills versus placebo or other comparator.
Target populations included adult heterosexual females, men
having sex with men, stable serodiscordant heterosexual couples,
and users of injectable recreational drugs. All trials were sponsored
by institutions based in the USA. The 11 approved protocols were
dated between 13 August 2004 and 29 May 2008. Five protocols
were versions 1.x, one was a version 2.0, three were version 3.x,
one was a version 4.0, and one was a version 7.0. Those protocols
were collected between October 2008 and January 2009 (Tables 1
and 2).
Ethics appraisal
All trials combined. Out of 101 checklist items, 14 were
found for all studies analyzed (as much as items were applicable);
43 were found for half studies or less; and six were found for no
study: strategy to ensure legitimacy of community partners chosen to represent
host community, randomized comparisons of behavioral risk-reduction
interventions incorporated into design, behavioral co-intervention was field
tested during planning phase, specification of measures taken to ensure
independence and competence of ethics review, specification of measures taken to
prevent situations of conflict(s) of interest, and strategy to assist local ethics
committee in reaching international standard procedures (Table S1). At
study level, adjusted percentages of ethics items reported, all
principles combined, were between 38% and 76% (median=58%;
interquartile range=51–68%). At principle level, median
percentages of ethics items reported, all studies combined, were
between 43% (social value) and 75% (informed consent and favorable
risk-benefit ratio) (Figure 1). Variations were noted in the percentage
of ethics items reported by principle, between individual studies,
especially for social value (Figure 2).
Efficacy/effectiveness trials (n=9) versus non-efficacy/
effectiveness trials (n=2). All median proportions of ethics
items reported for efficacy studies were equal to or higher than
corresponding values for studies not having efficacy/effectiveness
as a primary outcome. At study level, median percentage of ethics
items reported, all principles combined, was 61% (18% more than
for studies with other primary focus). At principle level, median
percentages of ethics items reported, all efficacy/effectiveness
studies combined, were between 50% (collaborative partnership) and
83% (fair selection of study population and informed consent) (Table 3).
Trials without USA site (n=3) versus trials with USA
site(s) (n=8). Most median proportions of ethics items reported
for studies without USA site were equal to or higher than
corresponding values for studies with USA site(s). Independent review
was the exception (5% fewer items reported for trials without USA
site). At study level, median percentage of ethics items reported, all
principles combined, was 63% (15% more than for studies with
USA site-s). At principle level, median percentages of ethics items
reported, all studies without USA site combined, were between
50% (collaborative partnership) and 83% (fair selection of study population)
(Table 3).
Trials fully or partially closed early (n=5) versus trials
not closed early (n=6). Most median proportions of ethics
items reported for studies closed early were higher than or equal to
corresponding values for studies not closed early. Scientific validity,
independent review and respect of recruited participants and study community
were exceptions (4%, 10%, and 5% fewer items reported for trials
closed early, respectively). At study level, median percentage of
ethics items reported, all principles combined, was 65% (9% more
than for studies not closed early). At principle level, median
percentages of ethics items reported, all early closures combined,
were between 50% (collaborative partnership and independent review) and
83% (fair selection of study population and informed consent). Studies
closed early following community pressure had fewer items
reported, compared to studies closed early based on stopping
rules defined a priori, except for respect of recruited participants and study
community (equal percentage) (Table 3).
Ethics guidelines reported
Ten protocol teams (91%) cited ethics guidance documents.
Nine of those mentioned international guidelines (Declaration of
Helsinki [54] or International Conference on Harmonisation-
Guidelines for Good Clinical Practice [55]) and/or guidelines
developed in sponsoring country (e.g., USA Code of Federal
HIV PrEP Ethics
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Lead investigator/
Registration code Sponsors Enrolled Population Countries
Celum/NCT00557245 BMGF, Gilead, UW (4700) serodiscordant couples (hetero) Kenya, Uganda
Chirenje/NCT00705679 CONRAD, Gilead, NIH (4200) females (hetero) Malawi, South Africa, Uganda, Zimbabwe
Choopanya/NCT00119106 CDC, Gilead (2400) females+males injecting
recreational drugs (unspecified
sexual orientation)
Thailand
Grant/NCT00458393 BMGF, Gilead, NIH 2499 males (homo) Brazil, Ecuador, Peru, South Africa,
Thailand, USA
Grohskopf/NCT00131677 CDC, Gilead 400 males (homo) USA
Hendrix/NCT00592124 CONRAD, Gilead, NIH 144 females (hetero) South Africa, Uganda, USA
Page-Shafer/NCT00078182 BMGF, FHI, Gilead, NIH 0 females (hetero) Cambodia
Peterson/NCT00122486 BMGF, FHI, Gilead, NIH 936 females (hetero) Cameroon, Ghana, Nigeria
Smith/NCT00111150 CDC, Gilead 71 females+males (hetero) Botswana
Thigpen/NCT00448669 CDC, Gilead (1200) females+males (hetero) Botswana
Van Damme/NCT00625404 BMGF, FHI, Gilead, USAID (3900) females (hetero) Kenya, Malawi, South Africa, Tanzania
Legend:
Registration code: as per the National Institute of Health trials registry.
Sponsors: BMGF=Bill and Melinda Gates Foundation; CDC=Centers for Disease Control and Prevention (United States of America); Gilead=Gilead Sciences
Incorporation; CONRAD=University of Eastern Virginia’s CONtraceptive Research & Development program; FHI=Family Health International; NIH=National Institutes of
Health (United States of America); USAID=United States Aid for International Development; UW=University of Washington.
Enrolled: number in brackets represent target sample sizes; other numbers are actual sample sizes reported.
Population: homo=homosexual; hetero=heterosexual.
Countries: USA=United States of America.
doi:10.1371/journal.pone.0022497.t001
Table 2. Design and progress status of the 11 PrEP trials appraised.
Lead investigator/
Registration code Pill(s) tested Comparator(s) Primary outcome(s)
Timeline (activation
to closure) Progress status
Celum/NCT00557245 1) FTC/TDF; 2) TDF matched placebo efficacy, safety 2008- ongoing
Chirenje/NCT00705679 1) FTC/TDF; 2) TDF 1) TDF gel; 2) matched
placebo pill; 3)
matched placebo gel;
effectiveness,
extended safety
2009- ongoing
Choopanya/NCT00119106 TDF matched placebo efficacy, safety 2005- ongoing
Grant/NCT00458393 FTC/TDF matched placebo efficacy, safety 2007–2010 completed
Grohskopf/NCT00131677 TDF 1) delayed TDF;
2) matched placebo;
3) delayed matched
placebo
extended safety,
tolerability
2005–2010 completed
Hendrix NCT00592124 TDF 1) TDF gel; 2) ‘‘self’’
(cross-over design)
adherence, acceptability,
pharmacokinetics
2008–2010 completed
Page-Shafer/NCT00078182 TDF matched placebo safety, efficacy 2004 closed early (community)
Peterson/NCT00122486 TDF matched placebo effectiveness,
extended safety
2004–2006 closed early (community)
Smith/NCT00111150 TDF matched placebo extended safety,
efficacy
2005–2007 closed early
(investigators:upgrade to
Thigpen’s trial)
Thigpen/NCT00448669 FTC/TDF matched placebo extended safety,
efficacy
2007–2009 closed early
(investigators:futility)
Van Damme/NCT00625404 FTC/TDF matched placebo effectiveness, safety 2009–2011 closed early
(investigators:futility)
Legend:
Registration code: as per the National Institute of Health trials registry.
Pill(s) tested: FTC=emtricitabine; TDF=tenofovir.
doi:10.1371/journal.pone.0022497.t002
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UNAIDS/AVAC’s Good Participatory Guidelines [14].
Discussion
Based on our analytic framework, 58% of 101 ethics items
relevant to HIV PrEP were found in study documents, on
average. As many as 43 of those items were reported for half
studies analyzed or less. We demonstrated variation in reporting
across the 11 studies appraised and across the eight ethical
principles explored. Our quantitative analytic strategy allowed
us to minimize assessment subjectivity. And Table S1 displays
data detailed enough to permit the reader to weigh the
importance of each item, based on his or her own perspective.
Rather than singling out individual trials (e.g., in Figure 2), we
chose to present results as aggregate figures so as to evaluate
HIV PrEP trials as a field, and hopefully generate constructive
discussions that may guide positive adjustments. Indeed, our
data suggest that ethics considerations reporting can be much
improved, overall.
Figure 1. Average percentages of ethics items reported, all studies combined. Legend: The first line represents the interquartile range of
standardized percentages of ethics items reported in PrEP trial documents, out of a list of 101 items, with the median percentage represented by a
diamond (all principles combined). The other 8 lines represent interquartile ranges of the percentages of items reported for each ethics principle
listed, with each median percentage represented by a square. The denominator used varied with ethics principles: 20 for collaborative partnership;7
for social value; 33 for scientific validity; 6 for fair selection of study population; 4 for favourable risk-benefit ratio; 10 for independent review; 12 for
informed consent; and 9 for respect for recruited participants and study community.
doi:10.1371/journal.pone.0022497.g001
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PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e22497At study level, more ethics considerations were reported for
efficacy/effectiveness trials than for trials focusing on other
primary questions (i.e., safety, tolerability, adherence, acceptabil-
ity, pharmacokinetics) –18% more checklist items, on average.
Sub-group analysis based on this factor also showed the largest
differences, in all but three principles. This is encouraging,
considering that efficacy trials are largest in sample sizes and that
their results are always highly anticipated for public health
decision-making [56]. However, as per the general trend, items
related to collaborative partnership, respect for recruited participants and
study community, and social value were the lowest reported in this
subset (50%, 56% and 57%, respectively). This seems dissonant
with the repeated argument that PrEP could be most beneficial to
populations living in areas of highest HIV prevalence [57–59].
More discussion is required regarding roll-out capacities and
planning.
Similarly, more ethics considerations were reported for studies
conducted outside of the USA, compared to studies with at least
one USA site (15% more checklist items, on average). Sub-group
analysis based on this factor showed the largest differences for
favorable risk-benefit ratio (25% more items, for trials outside the
USA). In our sample, all eight studies without USA sites have been
led, co-led and/or sponsored by USA-based institutions [15].
Other host communities were in low-and-middle income countries
(South-America, Sub-Saharan Africa, South-East Asia). Our
findings might reflect institutional limitations in clinical research
regulations, in those countries [60–62]. Multiple-level regulatory
reviews imposed on investigators may also influence reporting of
ethics-relevant matters in international trials.
Also, we found no correlation between study status and
percentage of ethics item reported: some ongoing/completed
trials had fewer ethics considerations reported than some trials
halted earlier (data not presented). This was unexpected since
ethics and methods concerns were clearly reported as leading
reasons for premature site closures [63]. At principle level, studies
closed early had fewer ethics items reported for scientific validity
(58%), independent review (50%) and respect for recruited participants and
study community (56%), compared with studies not closed prema-
turely (62%, 60% and 61%, respectively). Reporting of ethics
considerations was almost always lower for trials stopped following
community pressure, compared to trials closed early based on a
priori stopping rules. This suggest that 1) reporting ethics
considerations in protocols may not guarantee that studies will
be perceived as ethical in host community context; 2) gaps in scientific
validity, independent review, and respect for recruited participants and study
community may have been core issues in halted trials (although not
necessarily the cause of termination); 3) there is a need to further
promote and enforce ethics guidelines that were developed for
biomedical HIV prevention trials, and from which most of our
checklist items were derived [12–14].
The validity of our results should be considered in light of some
limitations. First, although our checklist was evidence-based, it was
developed without extensive experts’ consultation or external
validation [64]. Second, the analysis of a wider range of study
documents (e.g., standard operating procedures, clinical trial
agreements/contracts) could have allowed us to find more ethics
items reported. Besides, ethics guidance documents we used as
references were published after some studies were terminated;
however, the systematic nature of our appraisal provided a
framework common to all studies and facilitated synthesis. Also,
we chose to be conservative in equally weighing all ethics items -as
per Emanuel’s suggestion [19] - although some may have been
given more importance depending on perspective and context.
Additionally, documents obtained were at different stages of
revision, which may have affected comparability across studies.
Most importantly, we did not evaluate the actual conduct of HIV
Table 3. Median percentages of ethics items reported in PrEP study documents: sub-group ethics appraisal.
All
principles
combined
Collaborative
partnership
Social
value
Scientific
validity
Fair sselection
of study
population
Favorable
risk-benefit
ratio
Independent
review
Informed
consent
Respect for
recruited
participants
& study
community
Primary outcome
efficacy (n=9) 61 50 57 61 83 75 60 83 56
other outcome(s) (n=2) 43 30 8 43 42 63 55 48 56
Enrollment sites
no USA site (n=8) 63 50 57 59 83 75 55 79 56
at least 1 USA site (n=3) 48 35 17 52 67 50 60 50 56
Progress status
early closure (n=5) 65 50 57 58 83 75 50 83 56
2 community-triggered
early closures
53 40 43 47 58 63 45 71 56
3 investigators-triggered
early closures
71 50 86 58 83 75 60 83 56
no early closure (n=6) 56 50 29 62 67 63 60 54 61
doi:10.1371/journal.pone.0022497.t003
Figure 2. Percentage of ethics items reported: individual studies, by principle. Legend: each bar represents adjusted percentage of ethics
items documented for a given trial; bars are ordered from earliest to most recent trial, based on source documents’ date (not based on study
activation date).
doi:10.1371/journal.pone.0022497.g002
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reportedly addressed in selected documents. Moreover, we did not
consider larger, contextual or consequential ethics issues of
applying experimental evidence in settings other than communities
that hosted a trial (e.g., treatment accessibility, affordability,
sustainability). Finally, we only analyzed a sub-set of eligible
studies, despite methodical attempts to obtain all protocols.
Conclusion
Confidence in science requires trust in scientists, and transpar-
ency is needed to cultivate that at every stage of the research
process. It is commendable that some PrEP research sponsors now
make full-text protocols freely available while it was out of the
question, not so long ago. As the lead of the first PrEP trial that got
stopped following community pressure, Dr. Page-Shafer reported:
‘‘When concerns about the trial were first raised publicly, it became clear to us
that aspects of the trial plans were being portrayed inaccurately. At this point,
we proposed to our funding agencies that the then current protocol be posted on
our institutional websites, as a means of publicly presenting the trial status and
planning, but this proposal was rejected.’’ [3]. We believe that openly
available study protocols should be the norm [65], and checklists
like ours could facilitate ethics appraisal or serve as scales to
improve reporting quality of ethics considerations.
Harm prevention in clinical research requires harmonized views
on ethics principles between funders and hosts of PrEP research
projects, and functional regulatory mechanisms in both sponsoring
and hosting countries. Proclaimed ethics considerations should be
more clearly and more extensively addressed in protocols, so as to
alleviate legitimate concerns regarding actual trial conduct. And
we showed that there is room for improvement in that area.
Sustained vigilance is essential to keep ethics in the foreground
throughout the whole research process.
Supporting Information
Table S1 Number of study teams reporting each ethics
checklist item. In this table, the 8 principles are guidance terms
or expressions representing best practices ‘‘that should underlie the
conduct of biomedical and behavioral research involving human
subjects’’ (US National commission for the Protection of Human
Subjects of Biomedical and Behavioural Research. The Belmont
Report: Ethical Principles and Guidelines for the Protection of
Human Subjects of Research. 1979). The 31 benchmarks are
specific and practical considerations that are ‘‘to guide researchers
and research-ethics committees in assessing how well the
enumerated ethical principles have been fulfilled in particular
cases’’. The 8 principles and 31 benchmarks presented here were
proposed in 2004 (Emanuel EJ, Wendler D, Killen J, Grady C.
What makes clinical research in developing countries ethical? The
benchmarks of ethical research. J Infect Dis 2004; 189(5):930). The
101 ethics checklist items were formulated by the authors of the
present article (MBK, DAF, DWC). n=number of trials reporting
checklist item. N=number of trials for which checklist item is
relevant. * item irrelevant for the 1 trial designed to be conducted
in the USA only. ** item irrelevant for the 2 trials not designed to
focus on efficacy/effectiveness. *** item irrelevant for the 2 trials
designed to include only men.
(DOC)
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